Recently, findings related to NLRP3 inflammasome-associated agents and inhibitors for use in treating NAFLD/NASH in experimental models have supported this therapeutic approach and been demonstrated to have positive effects. Here, NLRP3 is linked to metabolic dysfunction-associated steatohepatitis.